Premium
Safety, bioavailability, and pharmacokinetics of VGX‐1027—A novel oral anti‐inflammatory drug in healthy human subjects
Author(s) -
Lee Jessica C.,
Menacherry Stanley,
Diehl Malissa C.,
Giffear Mary D.,
White C. Jo,
Juba Rob,
Bagarazzi Mark L.,
Muthumani Karuppiah,
Boyer Jean,
Agarwal Vipin,
Nicoletti Ferdinando,
Bart Stephen,
Kim J. Joseph,
Weiner David B.,
Sardesai Niranjan Y.
Publication year - 2015
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.193
Subject(s) - medicine , pharmacokinetics , tolerability , dosing , rheumatoid arthritis , pharmacology , bioavailability , adverse effect , drug , urine , oral administration
VGX‐1027, a novel oral immune modulator, is under development for the treatment of rheumatoid arthritis. The safety, tolerability, and pharmacokinetics of single (1–800 mg) and multiple (40–400 mg) oral doses were evaluated in 2 clinical studies. The doses were well tolerated up to 800 mg in a single dose and 200 mg twice daily in multiple doses. Adverse events were mild to moderate in severity with no identifiable dose‐related pattern. There were no clinically significant physical or laboratory findings. The pharmacokinetic data indicated that increases in C max and AUC 0−inf were dose‐proportional, and AUC 0− τ was approximately dose‐proportional. For the single‐dose study, median T max ranged from 0.5 to 2 hours and mean t 1/2 ranged from 4.9 to 8.7 hours. For the multiple‐dose study, median T max ranged from 0.5 to 2.0 hours and mean t 1/2 ranged from 7.05 to 10.05 hours. No accumulation of the drug was observed after day 1, indicating that steady‐state concentrations were attained with single and multiple dosing for 5 days. Approximately 90% of the administered dose was excreted in urine as unchanged drug.